症状性肺炎与杜尔瓦卢马布在同时进行化学放射治疗后在不可切割的III期NSCLC中
Johan F Vansteenkiste1, Jarushka Naidoo2,3, Corinne Faivre-Finn4
1Respiratory Oncology Unit and Trial Unit, Department of Respiratory Diseases, University Hospitals KU Leuven, Leuven, Belgium.
JTO clinical and research reports
|March 8, 2024
概括
杜尔瓦卢马布在化学放射治疗后改善了不可切除的III期NSCLC的存活率. 杜尔瓦卢马布治疗症状性肺炎的风险并不超过其对生存的益处.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 临床试验 临床试验
背景情况:
- 帕西菲克试验证明了杜尔瓦卢马布在化学放射治疗后不可切除的III期NSCLC中的疗效.
- 肺炎或辐射性肺炎 (PRP) 是一种常见的副作用,需要进一步研究其关联和影响.
研究的目的:
- 在接受杜尔瓦卢马布治疗的患者中,探索与症状 (级别≥2) PRP (G2+PRP) 相关的因素.
- 评估G2+PRP对无进展生存 (PFS) 和总生存 (OS) 的影响.
主要方法:
- 对第3期PACIFIC试验数据的探索性分析.
- 单变量和多变量逻辑回归以确定G2+PRP的风险因素.
- 考克斯的比例危险模型用于评估PFS和OS,调整为G2+PRP和其他共变量.
主要成果:
- G2+PRP发生在19.8%的杜尔瓦卢马布接受者和14.1%的安慰剂接受者中.
- 较高的G2+PRP风险与亚洲的治疗,IIIA阶段的疾病,性能状态1和没有先前的诱导化疗相关.
- 无论G2+PRP的发展如何,杜尔瓦卢马布的PFS和OS益处都保持不变.
结论:
- 特定的患者和治疗因素预测Durvalumab的G2+PRP风险更高.
- 在不可切除的III期NSCLC中,杜尔瓦卢马布的临床益处不会因G2+PRP的发生而减弱.
更多相关视频
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.6K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
相关概念视频
Pneumothorax-II
145
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
145
Pneumonia IV: Management
324
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
324
Pneumonia III: Complications and Assessment
209
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
209
Pneumonia II: Pathophysiology
269
The pathophysiology of pneumonia involves the following steps:
269
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
